Ciclesonide: A novel inhaled corticosteroid

Expert Opinion on Investigational Drugs

Volumn 13, Issue 10, 2004, Pages 1349-1360

  Humbert, Marc ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Asthma; Ciclesonide; Economic impact; Epidemiology; Glucocorticoid; Inhaled corticosteroid; Metered dose inhaler; Receptor binding

Indexed keywords

BUDESONIDE; CICLESONIDE; CORTICOSTEROID; DESISOBUTYRYLCICLESONIDE; DRUG METABOLITE; FLUTICASONE PROPIONATE; UNCLASSIFIED DRUG;

ADRENAL CORTEX INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CATARACT; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSPHONIA; GLAUCOMA; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HOARSENESS; HUMAN; INTRAOCULAR HYPERTENSION; METERED DOSE INHALER; PHARMACODYNAMICS; PHARYNGITIS; SINGLE DRUG DOSE; SKIN ATROPHY; SKIN BRUISING; THRUSH;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; PREGNENEDIONES; TREATMENT OUTCOME;

EID: 5444253912     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.10.1349     Document Type: Article

References (70)

1. LIN H, CASALE TB: Treatment of allergic asthma. Am. J. Med. (2002) 113(Suppl. 9A): 8S-16S.
2. KHERADMAND F, RISHI K, CORRY DB: Environmental contributions to the allergic asthma epidemic. Environ. Health. Perspect. (2002) 110 (Suppl. 4):553-556.
3. MANNINO DM, HOMA DM, AKINBAMI LJ, MOORMAN JE, GWYNN C, REDD SC: Surveillance for asthma-United States, 1980-1999. MMWR. Surveill. Summ. (2002) 51: 1-13.
4. REDD SC: Asthma in the United States: burden and current theories. Environ. Health. Perspect. (2002) 110 (Suppl. 4):557-560.
5. Self-reported asthma prevalence and control among adults-United States, 2001. MMWR. Morb. Mortal. Wkly. Rep. (2003) 52: 381-384.
6. NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM. EXPERT PANEL REPORT. Guidelines for the diagnosis and management of asthma update on selected topics-2002. J. Allergy. Clin. Immunol. (2002) 110 (5 Suppl.):S141-S219.
7. ALLEN DB, BIELORY L, DERENDORF H, DLUHY R, COLICE GL, SZEFLER SJ: Inhaled corticosteroids: past lessons and future issues. J. Allergy. Clin. Immunol. (2003) 112 (Suppl.):S1-S40.
8. ROHATAGI S, APPAJOSYULA S, DERENDORF H et al.: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clin. Pharmacol. (2004) 44: 37-47.
9. DE LONGUEVILLE M: What are the candidate groups for pharmacotherapeutic intervention to prevent asthma? Pediatr. Allergy. Immunol. (2000) 11 (Suppl. 13):41-44.
10. FOUCARD T: Is prevention of allergy and asthma possible? Acta Paediatr. Suppl. (2000) 89: 71-75.
11. BECKER AB, CHAN-YEUNG M: Primary prevention of asthma. Curr. Opin. Pulm. Med. (2002) 8: 16-24.
12. BHALAY G, SANDHAM DA: Recent advances in corticosteroids for the treatment of asthma. Curr. Opin. Investig. Drugs (2002) 3 1149-1156.
13. RODRIGO GJ: Inhaled therapy for acute adult asthma. Curr. Opin. Allergy Clin. Immunol. (2003) 3: 169-175.
14. UMLAND SP, SCHLEIMER RP, JOHNSTON SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm. Pharmacol. Ther. (2002) 15: 35-50.
15. PELAIA G, VATRELLA A, CUDA G, MASELLI R, MARSICO SA: Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life. Sci. (2003) 72: 1549-1561.
16. CAVE A, ARLETT P, LEE E: Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol. Ther. (1999) 83: 153-179.
17. LIPWORTH BJ: Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch. Intern. Med. (1999) 159: 941-955.
18. CAMPBELL LM: Once-dady inhaled corticosteroids in mild to moderate asthma. Improving acceptance of treatment. Drugs (1999) 58 (Suppl. 4):25-33.
19. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N. Engl. J. Med. (2000) 343: 1054-1063.
20. JACKSON LD, POLYGENIS D, MCIVOR RA, WORTHINGTON I: Comparative efficacy and safety of inhaled corticosteroids in asthma. Can. J. Clin. Pharmacol. (1999) 6: 26-37.
21. KELLY HW, NELSON HS: Potential adverse effects of the inhaled corticosteroids. J. Allergy. Clin. Immunol. (2003) 112: 469-478.
22. DUBUS JC, MARGUET C, DESCHILDRE A et al.: Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy (2001) 56: 944-948.
23. JOGUPARTHI V, BREEN P, COMPADRE C et al.: Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. J. Aerosol. Med. (2003) 16: 47-53.
24. GOLDIN JG, TASHKIN DP, KLEERUP EC et al: Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J. Allergy. Clin. Immunol. (1999) 104: S258-S267.
25. CORREN J, TASHKIN DP: Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin. Ther. (2003) 25: 776-798.
26. LEACH CL, DAVIDSON PJ, BOUDREAU RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. (1998) 12: 1346-1353.
27. SUISSA S, BALTZAN M, KREMER R, ERNST P: Inhaled and nasal corticosteroid use and the risk of fracture. Am. J. Respir. Crit. Care. Med. (2004) 169: 83-88.
28. HUBBARD RB, SMITH CJ, SMEETH L, HARRISON TW, TATTERSFIELD AE: Inhaled corticosteroids and hip fracture: a population-based case-control study. Am. J. Respir. Crit. Care. Med. (2002) 166: 1563-1566.
29. ANHOJ J, BISGAARD AM, BISGAARD H: Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics (2002) 109: E40.
30. MEALY NE, BAYÉS M, CASTAÑER J: Ciclesonide. Drugs Fut. (2001) 26: 1033-1039.
31. DIETZEL K, ENGELSTÄTTER R, KELLER A: Cidesonide: an on-site-activated steroid. In: New Drugs for Asthma, Allergy and COPD. TT Hansel, PJ Barnes (Eds), Karger, Basel, Switzerland (2001) 31 91-93.
32. MUTCH E, NAVE R, ZECH K, WILLIAMS FM: Esterases involved in the hydrolysis of ciclesonide in human tissues. Eur. Respir. J. (2003) 22 (Suppl. 45):267s.
33. BETHKE T, NAVE R, ZECH K, GUNAWARDENA K: Pharmacokinetics of ciclesonide and its active principle in asthma patients and healthy subjects after single dose inhalation. J. Allergy Clin. Immunol. (2003) 111: S217.
34. BERGER WE, MANSFIELD L, PINTER C et al.: Ciclesonide is well tolerated and has minimal oropharyngeal side effects at once-daily doses of 80 μg, 160 μg, and 320 μg in the treatment of patients with mild-to-moderate asthma. J. Allergy Clin. Immunol. (2004) 113 S38.
35. 20 for adenosine in asthma patients [poster]. Proceedings of the 98th International Conference of the American Thoracic Society (ATS). Atlanta, Georgia, USA (2002).
36. NAVE R, DROLLMANN A, MEYER W, ZECH K: In vivo epimeric stability of ciclesonide. Am. J. Respir. Crit. Care Med. (2003) 167: A771.
37. STOECK M, RIEDEL R, HOCHRAUS G et al.: In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J. Pharmacol. Exp. Ther. (2004) 309: 249-258.
38. DERENDORF H: Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. (1997) 91(Suppl. A): 22-28.
39. BUNDSCHUH DS, MARX D, HATZELMANN A et al.: Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide. Proceedings of the 11th Annual Congress of the European Respiratory Society (EAS). Berlin, Germany (2001).
40. BELVISI MG, BUNDSCHUH DS, STOECK M et al.: Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma Proceedings of the 11th Annual Congress of the European Respiratory Society (ERS). Berlin, Germany (2001).
41. ROHATAGI S, ARYA V, ZECH K et al.: Population pharmacokinetics and pharmacodynamics of cidesonide. J. Clin. Pharmacol. (2003) 43: 365-378.
42. ROHATAGI S, DERENDORF H, ZECK K: PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide. J. Allergy Clin. Immunol. (2003) 111: S218.
43. 14C]-ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. (2004) 43: 479-486.
44. NAVE R, BETHKE TD, SEIBERLING M, STEINIJANS VW, ZECH K: Pharmacokinetics and phannacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. Eur. Respir. J. (2002) 20(Suppl. 38): 110s.
45. NAVE R, ZECH K, BETHKE TD: Oropharyngeal deposition of inhaled ciclesonide and budesonide in healthy subjects. J. Allergy Clin. Immunol. (2003) 111: S220.
46. RICHTER K, NAVE R, BIBERGER C, BETHKE T, MAGNUSSAN H: Low oropharyngeal deposition of inhaled ciclesonide in healthy subjects and asthma patients. Proceedings of the 4th Triennial World Asthma Meeting 2004 (WAM). Bangkok, Thailand (2004).
47. RICHTER K, NIELSEN-GODE D, BIBERGER C, NAVE R, MAGNUSSEN H: Oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in asthmatics. Proceedings of the 98th International Conference of the American Thoracic Society (ATS). Atlanta, Georgia, USA (2002).
48. HALL M, PEET CF, BODDINGTON TKS, ENOS T, NAVE R, ZECH K: Enzymology of the human hepatic metabolism of ciclesonide (B9207-015). Proceedings of the 15th Annual Meeting of the Japanese Society for the Study of Xenobiotics. Fukuoka, Japan (2000).
49. NAVE R, SÄTTELE N, MEYER W, FUHST R, ZECH K: Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. Am. J. Respir. Crit. Care Med. (2003) 167: A771.
50. NAVE R, FISHER R, ZECH K: In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. Am. J. Respir. Crit. Care Med. (2003) 167: A771.
51. LARSEN BB, NIELSEN LP, ENGELSTÄTTER R, STEINIJANS V, DAHL R: Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy (2003) 58: 207-212.
52. KANNIESS F, RICHTER K, BÖHME S, JÖRRES RA, MAGNUSSEN H: Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm. Pharmacol. Ther. (2001) 14: 141-147.
53. TAYLOR DA, JENSEN MW, KANABAR V et al.: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am. J. Respir. Crit. Care Med. (1999) 160: 237-243.
54. POSTMA DS, SEVETTE C, MARTINAT Y, SCHLÖSSER N, AUMANN J, KAFÉ H: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. (2001) 17: 1083-1088.
55. WEINBRENNER A, HÜNEKE D, ZSCHIESCHE M et al.: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J. Clin. Endocrinol. Metab. (2002) 87: 2160-2163.
56. ENGELSTÄTTER R, LANGDON C, BETHKE T, RATHGEB F, STEINIJANS VW, WURST W: Efficacy of ciclesonide after twelve-week treatment of bronchial asthma [poster]. Proceedings of the 98th International Conference of the American Thoracic Society. Atlanta, Georgia, USA (2002).
57. CHAPMAN KR, PATEL P, D'URZO AD et al.: Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy (2004) (In press).
58. LANGDON CG, ADLER M, MEHRA S, DROLLMANN A: Ciclesonide is effective in the treatment of asthma: a 12-week, placebo-controlled study. Proceedings of the 4th Triennial World Asthma Meeting 2004 (WAM). Bangkok, Thailand (2004).
59. O'CONNOR B, SIPS P, ENGELSTÄTTER R, STEINIJANS VW, WURST W: Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial. Proceedings of the 98th International Conference of the American Thoracic Society (ATS). Atlanta, Georgia, USA (2002).
60. UKENA D, BIBERGER C, VON BEHREN V et al.: Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study. Eur. Respir. J. (2003) 22(Suppl. 45): 411s.
61. BOULET L-P, ENGELSTATTER R, MAGYAR P, TIMAR M, KNIGHT A, FABBRI L: Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma. Am. J. Respir. Crit. Care Med (2003) 167: A771.
62. ENGELSTÄTTER R, BENEZET O, KAFÉ H et al.: Comparative study in asthma patients treated with inhaled ciclesonide (80 μg or 320 μg once daily) or budesonide (200 μg twice daily) for 12 weeks. Am. J. Repir. Crit. Care Med. (2003) 167: A771.
63. BUHL R, VINKLER I, MAGYAR P et al.: Once daily ciclesonide is as effective as fluticasone propionate given twice daily in treating patients with asthma. Am. J. Respir. Crit. Care Med. (2004) 169: A91.
64. CHAPMAN KR, PATEL P, BOULET LP et al.: Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study. Eur. Respir. J. (2002) 20(Suppl. 38): 373s.
65. O'CONNOR BJ, KILFEATHER S, CHEUNG D et al.: Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Eur. Respir. J. (2002) 20 (Suppl. 38):406s.
66. SZEFLER SJ, HERRON J, LLOYD M et al.: High doses of the novel inhaled steroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma. J. Allergy Clin. Immunol. (2003) 111: S216.
67. LAFORCE CF, BAKER JW, AMIN D et al.: Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary-adrenal (HPA)-axis function in mild-to-moderate asthmatics. J. Allergy. Clin. Immunol. (2003) 111: S218.
68. BERNSTEIN JA, NOONAN M, RIM C et al.: Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma. J. Allergy. Clin. Immunol. (2004) 113 S113.
69. KALINER M, WHITE M, CHERVINSKY P et al.: Ciclesonide, a novel inhaled corticosteroid (ICS), does not suppress hypothalamic-pituitary-adrenal (HPA)-axis function. Proceedings of the World Allergy Organization Congress-XVIII ICACI. Vancouver, Canada (2003) (Abstract O-17-1).
70. MARTIN RJ, SZEFLER SJ, CHINCHILLI VM et al.: Systemic effect comparisons of six inhaled corticosteroid preparations. Am. J. Respir. Crit. Care. Med. (2002) 165: 1377-1383.